News / Reuters
19 fans
View all »Members who favorited this news source
-
Tiffrod (Tiffany Taylor)
-
lenatcl (Lena T)
-
benwildeboer (Ben Wildeboer)
-
FrankRegan (Frank Regan)
-
proletarianlibrarian
Popular stories
-
Obama speech stage resembles ancient Greek temple
http://www.reuters.com/article/politicsNews/idUSN26369790200...DENVER (Reuters) - Democratic presidential candidate Barack Obama's big speech on Thursday night will be delivered from an elaborate columned stage resembling a miniature Greek temple.
1 day ago -
Iraq PM says U.S. agrees to withdraw troops by 2011
http://www.reuters.com/article/topNews/idUSLP66354720080825?...BAGHDAD (Reuters) - Iraqi Prime Minister Prime Nuri al-Maliki said on Monday that an agreement had been reached in negotiations on a security pact with the United States to end any foreign military presence in Iraq by the end of 2011.
2 days ago -
No nuns on catwalk, priest stops "beauty contest"
http://www.reuters.com/article/oddlyEnoughNews/idUSLQ2853162...ROME (Reuters) - An Italian priest who had planned an online "pageant" for nuns has suspended the project, saying he was misinterpreted and had no intention of putting sisters on a beauty catwalk.
1 day ago
271,411 blog reactions
-
While You Were at the Beer Festival II
http://invivoblog.blogspot.com/2008/08/while-you-were-at-bee...ring Zing. There was little industry news with zing over the weekend, so we've put on the beer goggles so you don't have to: Pfizer has reached another settlement over a generic Lipitor, Reuters reports, though there are no details available regarding the Big Pharma's deal with Apotex. IMC11F8 is the catchy name given to Imclone's next-generation, fully human antibody viewed by many as a son-of- Erbitux. The candidate, not yet in pivotal trials, is at the core of the ongoing BMS/Imclone negotiation, points out today's Wall
-
DotW: Dog Days
http://invivoblog.blogspot.com/2008/08/dotw-dog-days.htmlpharma is behaving more like a dog with a bone, threatening to turn hostile if Alpharma's board refuses to accept the bid, which it apparently presented to the company in early August. Alpharma execs weren't available for comment--of course--but Reuters reports that the company appears to have rejected the bid. King's offer of $33 a share represents a 37% premium over the $24.04 closing price of Alpharma's stock on August 21. Not too surprisingly, Alpharma shares surged 41% premarket to $34, while King fell 1% to $11.12. By
-
Proteostasis Proves Platform Companies Still In Vogue
http://invivoblog.blogspot.com/2008/08/proteostasis-proves-p...emerging field called epigenetics, pulled in $32 million in financing from Third Rock Ventures, The Column Group, and Venrock Associates. Meanwhile, Third Rock joined returning seed investors Flagship Ventures and Arch Venture Partners in July to fund Agios, which is focused on cancer metabolism and therapeutics targeting a poorly understood cellular process called autophagy. Like Constellation and Agios, Proteostasis Therapeutics is of a type: A-list investors, top management, and hot science. Mention the
